Iron-Deficiency Anemia

Iron-deficiency anemia is a form of anemia in which insufficient available iron limits the production of hemoglobin, the oxygen-carrying protein in red blood cells. It represents a later stage of iron deficiency: iron stores can become depleted before hemoglobin falls below the threshold defining anemia. Established disease commonly produces smaller, less hemoglobin-rich red blood cells, although these changes are not present in every case. (ods.od.nih.gov)

Iron-deficiency anemia is the most common form of anemia and an important public health concern. It can result from inadequate dietary iron, increased requirements during growth or pregnancy, impaired absorption, or blood loss. Its significance extends beyond fatigue and reduced physical capacity: it can accompany developmental and pregnancy-related complications and can indicate an underlying bleeding disorder or gastrointestinal disease. (nhlbi.nih.gov)

Diagnosis combines evidence of anemia with assessment of iron status, particularly ferritin, while accounting for the effects of inflammation on laboratory results. Clinical management addresses both iron depletion and its underlying cause. The subject therefore spans iron physiology, population nutrition, laboratory diagnosis, investigation of blood loss, and iron-replacement therapies. (bsg.org.uk)

Definition and Boundaries

Iron-deficiency anemia (IDA) is anemia attributable to an inadequate supply of iron for hemoglobin synthesis. Iron is an essential component of hemoglobin, the oxygen-carrying protein in red blood cells. The definition therefore requires both a hemoglobin concentration below the appropriate threshold and evidence that iron deficiency contributes to that reduction. Iron deficiency alone is not synonymous with IDA: body iron stores can decline, and iron supply to developing red cells can become insufficient, while circulating hemoglobin remains within the normal range. The US National Institutes of Health distinguishes storage depletion, iron-deficient erythropoiesis, and iron-deficiency anemia as successive stages of deficiency. These are distinctions in iron status, not interchangeable diagnostic labels. (ods.od.nih.gov)

Anemia is defined by blood hemoglobin concentration relative to age, sex, and physiological state—not by serum iron concentration alone. The World Health Organization’s 2024 guideline, for example, defines anemia in adults aged 15–65 years as hemoglobin below 120 g/L in nonpregnant women and below 130 g/L in men. Separate thresholds apply to children and to different trimesters of pregnancy. These cutoffs identify anemia of any cause; they do not establish that the cause is iron deficiency. Consequently, a low hemoglobin result and a low iron-status marker answer different questions: whether anemia is present and whether iron availability or reserves are impaired. (ncbi.nlm.nih.gov)

Absolute iron deficiency means that total body iron stores are inadequate to meet requirements. Ferritin provides a laboratory indicator of these reserves, and a falling ferritin concentration can reveal depletion before anemia develops. Thus, a person with depleted stores but hemoglobin above the applicable anemia threshold has iron deficiency without anemia. Conversely, anemia without evidence of iron deficiency remains a broader diagnostic category. Establishing IDA requires combining the assessment of hemoglobin with evidence of iron deficiency rather than treating either finding as sufficient by itself. (ods.od.nih.gov)

Functional iron restriction, often termed functional iron deficiency, describes inadequate iron delivery for red-cell production despite apparently adequate stored iron. The distinction is between the amount stored and the amount available to the bone marrow. The regulatory hormone hepcidin can limit intestinal iron absorption and the availability of stored iron. Functional restriction occurs in chronic kidney disease and chronic inflammatory conditions; it can contribute to anemia without the depleted reserves characteristic of uncomplicated absolute deficiency. The British Society of Gastroenterology’s 2021 guideline explicitly separates these two forms of iron deficiency. (doi.org)

Absolute deficiency and functional restriction can coexist. In inflammatory bowel disease, for example, depleted reserves may occur alongside inflammation-related restriction of iron availability. Inflammation can also raise ferritin, so an apparently normal ferritin concentration does not necessarily demonstrate adequate stores. Anemia of inflammation therefore overlaps with IDA when absolute deficiency is also present, but is not synonymous with it: restricted iron availability is only one component of inflammatory anemia. (ods.od.nih.gov)

Iron Physiology and Disease Development

Dietary iron occurs in heme and nonheme forms. Heme consists of iron bound within a protoporphyrin ring and is supplied by meat, poultry, and seafood; these foods also contain nonheme iron, the form found in plant foods and iron-fortified products. Absorption occurs predominantly in the duodenum and proximal jejunum. Nonheme iron crosses the intestinal absorptive cell’s apical membrane through divalent metal transporter 1; iron subsequently exits across the basolateral membrane through ferroportin. Heme-derived iron also enters the intracellular iron pool, although the mechanisms of heme uptake are less completely characterized. Iron retained within intestinal cells rather than exported can be lost when those cells are shed. (ods.od.nih.gov)

In plasma, transferrin binds iron and transports it to tissues, particularly the erythroid precursors in bone marrow that synthesize hemoglobin. Transferrin–iron complexes bind cell-surface receptors and enter cells by endocytosis; the released iron is delivered to mitochondria for heme synthesis. Adults contain approximately 3–4 g of iron, most of it in hemoglobin. Storage iron is held chiefly in ferritin and hemosiderin, a ferritin-derived storage material, in the liver, spleen, and marrow. Recycling supplies far more iron than intestinal absorption: macrophages recover approximately 20–25 mg daily from aging erythrocytes, whose usual lifespan is about 120 days, whereas absorption of roughly 1–2 mg daily ordinarily replaces external losses. (pmc.ncbi.nlm.nih.gov)

Hepcidin, a peptide hormone produced chiefly by the liver, regulates the entry of iron into plasma. Its target, ferroportin, exports iron from intestinal cells, iron-recycling macrophages, and hepatocytes. In 2004, Elizabeta Nemeth and colleagues demonstrated that hepcidin binds ferroportin and induces its internalization and degradation, reducing cellular iron export. Higher hepcidin therefore limits both dietary iron delivery and release of recycled or stored iron. Iron depletion and increased erythropoietic demand normally suppress hepcidin, allowing greater absorption and mobilization of reserves. Because humans lack a substantial regulated pathway for iron excretion, control of absorption and redistribution is central to iron homeostasis. (pubmed.ncbi.nlm.nih.gov)

Inflammation can alter this response: inflammatory signaling increases hepcidin production, retaining iron in macrophages and other storage cells while reducing intestinal iron delivery. The marrow may consequently receive insufficient iron even when total stores are not depleted—a mechanism termed functional iron restriction. For example, iron recovered from old erythrocytes may remain within macrophages instead of returning promptly to plasma transferrin. Absolute depletion and inflammatory restriction can coexist. Ferritin may also rise during inflammation, so its circulating concentration does not always reflect the amount of iron readily available for erythropoiesis. (pubmed.ncbi.nlm.nih.gov)

With sustained negative iron balance, storage reserves decline first, while hemoglobin concentration can remain normal. As reserves become exhausted, transferrin saturation falls and iron delivery to erythroid precursors becomes inadequate: this is iron-deficient erythropoiesis, which precedes overt anemia. Further restriction reduces heme and hemoglobin synthesis until circulating hemoglobin falls below the applicable normal range. Newly produced cells contain less hemoglobin—hypochromia—and commonly become smaller—microcytosis. These changes correspond respectively to reduced mean corpuscular hemoglobin and mean corpuscular volume. They develop progressively rather than appearing together at a single threshold; hypochromia can be detectable before pronounced microcytosis, and normal average cell size does not exclude early iron deficiency. (ods.od.nih.gov)

Causes of Negative Iron Balance

Negative iron balance develops when absorbed dietary iron cannot replace iron lost from the body or meet the additional needs of growth and reproduction. Blood loss, inadequate intake, and impaired absorption frequently coexist rather than acting as mutually exclusive causes. For example, menstrual losses may become consequential when dietary iron availability is low, while intestinal disease may combine bleeding with malabsorption. The 2021 British Society of Gastroenterology guideline identifies menstrual bleeding, blood donation, inadequate diet, gastrointestinal surgery, and long-term medication exposure among the relevant contributing factors. (doi.org)

Blood loss removes iron contained in hemoglobin within circulating red blood cells. Heavy menstrual bleeding and hemorrhage during childbirth are important reproductive sources; gastrointestinal losses may arise from peptic ulcers, inflammatory bowel disease, or colorectal cancer. Gastrointestinal bleeding can be recurrent without being visibly apparent. Urinary tract bleeding, traumatic injury, and operative bleeding provide additional routes of loss. Aspirin and other nonsteroidal anti-inflammatory drugs, including ibuprofen and naproxen, can cause gastrointestinal bleeding and thereby contribute to iron depletion. (nhlbi.nih.gov) Repeated blood donation is another cumulative source: a 450 mL whole-blood donation removes approximately 200–250 mg of iron. Successive donations can deplete stores when replacement between donations is incomplete, even before anemia develops. (ncbi.nlm.nih.gov)

Inadequate intake and increased requirements are especially important when the amount of iron supplied does not keep pace with tissue growth. During infancy, iron-rich complementary foods become important because breast milk alone does not supply enough iron beyond approximately four to six months. Adolescence combines rapid growth with, in menstruating adolescents, an additional source of blood loss. Pregnancy increases iron requirements for maternal and fetal needs. The US recommended dietary allowance illustrates these life-stage differences: 11 mg/day at 7–12 months; 11 mg/day for boys and 15 mg/day for girls aged 14–18 years; and 27 mg/day during pregnancy, compared with 18 mg/day for nonpregnant women aged 19–50 years. These are dietary reference values for healthy populations, not treatment doses or amounts that must all be absorbed. (ods.od.nih.gov)

Dietary iron quantity is distinct from bioavailability. Heme iron in meat and seafood is generally more readily absorbed than nonheme iron in plant foods and fortified products. The NIH Office of Dietary Supplements estimates iron bioavailability at approximately 14–18% from mixed diets containing substantial meat, seafood, and vitamin C, compared with 5–12% from vegetarian diets. Vitamin C enhances nonheme iron absorption, whereas phytates and certain polyphenols inhibit it. These percentages describe overall dietary patterns rather than fixed absorption rates for every meal; a diet containing an apparently adequate iron quantity may still provide insufficient absorbable iron. (ods.od.nih.gov)

Malabsorption limits iron acquisition despite dietary availability. Celiac disease produces gluten-triggered immune injury to the small intestine, reducing nutrient absorption; the 2021 British Society of Gastroenterology guideline reports celiac disease in approximately 3–5% of iron-deficiency anemia cases. (niddk.nih.gov) Gastrectomy, small-bowel resection, and gastric bypass can impair iron uptake by altering gastric function or bypassing absorptive bowel. Atrophic gastritis and Helicobacter pylori infection are also recognized contributors. Long-term proton pump inhibitor use may reduce absorption through suppression of gastric acid, a different mechanism from medication-induced bleeding. In inflammatory bowel disease, bleeding and impaired absorption can coexist with inflammation-mediated iron restriction; the latter concerns iron availability rather than necessarily representing net loss of body iron. (pmc.ncbi.nlm.nih.gov)

Epidemiology and Population Burden

The population burden of iron-deficiency anemia cannot be inferred directly from the prevalence of all-cause anemia. Hemoglobin-based surveys identify anemia but do not establish its cause; iron-status measurements distinguish iron deficiency with anemia from iron deficiency without anemia. The World Health Organization (WHO), in its 2025 estimates, reported that all-cause anemia affected 30.7% of women aged 15–49 years worldwide in 2023, including 35.5% of pregnant women and 30.5% of nonpregnant women. Its estimate for children aged 6–59 months was 39.8% in 2019. These figures describe anemia from all causes, not iron-deficiency anemia, and the different reference years must be retained when comparing populations. (ncbi.nlm.nih.gov)

Age and reproductive status shape the distribution of risk. Infants and children younger than two years, menstruating adolescents and adults, and pregnant and postpartum women are particularly vulnerable; rapid growth, menstrual losses, increased requirements during pregnancy, and childbirth-related blood loss contribute to this pattern. Geographic differences also reflect overlapping nutritional, infectious, and inherited causes. WHO identifies Africa and South-East Asia as the regions most affected by all-cause anemia, and reports greater burdens in low- and lower-middle-income countries, rural populations, poorer households, and people without formal education. These patterns indicate important social determinants of health, but do not establish what proportion of anemia in any particular setting is attributable to iron deficiency. (who.int)

Population surveys that measure both hemoglobin and iron status demonstrate the distinction quantitatively. An analysis of the United States National Health and Nutrition Examination Survey (NHANES), published in 2016 using 2007–2010 data, estimated that among children aged 1–5 years, 7.1% had iron deficiency, 3.2% had anemia, and 1.1% had iron-deficiency anemia; the latter estimate had a 95% confidence interval of 0.6–1.7%. Among children aged 1–2 years, the corresponding estimates were 13.5%, 5.4%, and 2.7%. Thus, approximately half of anemic children in the younger group were iron deficient, rather than all anemic children. The study defined iron deficiency using calculated total-body iron below zero and anemia using hemoglobin below 110 g/L. (pmc.ncbi.nlm.nih.gov)

A separate NHANES analysis of 2007–2010 data found iron deficiency in 10.4% of nonpregnant US females aged 15–49 years and iron-deficiency anemia in 5.0% (95% confidence interval, 4.2–5.8%). Iron-deficiency anemia was defined by both negative calculated total-body iron and hemoglobin below 120 g/L. Its prevalence was 6.1% among women aged 35–49 years, compared with 3.7% among those aged 20–34 years. Women with two or more previous births also had higher prevalence than women with one previous birth. These dated estimates illustrate variation within a high-income country rather than supplying a universal prevalence or a current national estimate. (pmc.ncbi.nlm.nih.gov)

Food insecurity can constrain access to a diverse, iron-containing diet, while infection can increase iron losses independently of food intake. Hookworm infection and schistosomiasis cause nutrient loss through bleeding; malaria and other infections can produce anemia through additional mechanisms, so infection-associated anemia is not automatically iron-deficiency anemia. Diagnostic capacity also affects the burden that is detected and classified. Hemoglobin testing alone leaves iron status unresolved, whereas access to ferritin testing permits detection of depleted stores, including before anemia develops. Because inflammation can elevate ferritin and conceal deficiency, WHO’s 2020 guidance supports concurrent inflammatory-marker measurements in populations with widespread infection or inflammation. Consequently, differences in testing availability, assay thresholds, and inflammation adjustment can influence apparent geographic or temporal differences in prevalence as well as opportunities for early detection. (who.int)

Clinical Manifestations and Consequences

Mild iron-deficiency anemia may be asymptomatic, particularly when it develops gradually. Common manifestations include fatigue, weakness, pallor, headache, dizziness, exertional breathlessness, and palpitations. These findings are nonspecific: they occur in other forms of anemia and in conditions unrelated to iron status. Symptom severity depends not only on the hemoglobin concentration but also on the speed of its decline and the individual’s cardiopulmonary reserve. Consequently, slowly developing anemia can produce fewer symptoms than a comparable reduction occurring rapidly; absence of symptoms does not exclude the disease. (nhlbi.nih.gov)

Several associated findings are more suggestive of iron deficiency, although none establishes the diagnosis independently. The British Society of Gastroenterology’s 2021 guidelines identify pica, particularly pagophagia—craving or repeatedly consuming ice—alongside koilonychia, glossitis, and angular stomatitis. Koilonychia describes concave, spoon-shaped nails; glossitis may present as a sore, smooth tongue; angular cheilitis involves inflammation or fissuring at the corners of the mouth. Restless legs syndrome is another association: an urge to move the legs, often accompanied by unpleasant sensations, becomes prominent during rest and in the evening or night, and is temporarily relieved by movement. Its sleep-disrupting effects can add to daytime tiredness. These features are clinical clues rather than substitutes for laboratory confirmation of anemia and iron depletion. (doi.org)

Reduced hemoglobin lowers the blood’s oxygen-carrying capacity, helping explain diminished exercise tolerance and breathlessness during activities such as climbing stairs. Fatigue and impaired physical performance can interfere with work, daily activities, and quality of life. Iron deficiency also affects processes beyond oxygen transport, because iron participates in muscle metabolism and cellular functioning. Cardiovascular compensation for anemia includes increased cardiac output; when anemia is severe, the additional circulatory demand can contribute to cardiac strain. Chest pain may occur, particularly where cardiovascular reserve is already limited, and severe anemia can be associated with heart failure. These complications are not inevitable consequences of mild disease, and their occurrence depends on severity and accompanying illness. (ods.od.nih.gov)

During pregnancy, iron-deficiency anemia is associated with preterm birth, low birthweight, and perinatal mortality. Such associations do not establish that iron deficiency alone causes every adverse outcome: maternal nutritional status, concurrent disease, and other determinants can influence both anemia and pregnancy outcomes. Evidence from intervention studies addresses a different question from observational associations. The NIH Office of Dietary Supplements reports that randomized trials show iron supplementation can reduce maternal iron-deficiency anemia and some adverse infant outcomes, while also noting uncertainty about the overall benefits of routine screening and supplementation in asymptomatic pregnant populations. Thus, demonstrated improvement in iron status should not be equated automatically with prevention of every associated obstetric complication. (ods.od.nih.gov)

In children, iron-deficiency anemia is associated with developmental delays and poorer cognitive or behavioral functioning. A 2006 longitudinal study by Betsy Lozoff, Elias Jimenez, and Julia B. Smith followed 185 Costa Rican participants initially enrolled at 12–23 months of age. Among participants from middle-socioeconomic-status families, those classified as having chronic iron deficiency in infancy had cognitive scores averaging 8–9 points below those with good infant iron status through age 19. Importantly, the exposure category included persistent iron deficiency as well as low-hemoglobin cases, rather than iron-deficiency anemia alone. The observational design documents a lasting association but does not, by itself, prove an isolated causal effect of anemia or establish that every affected child will experience persistent impairment. (nhlbi.nih.gov)

Laboratory Diagnosis and Differential Diagnosis

The complete blood count establishes the presence of anemia and characterizes red-cell abnormalities. Reduced hemoglobin concentration is commonly accompanied by a low mean corpuscular volume (MCV), indicating microcytosis, and a low mean corpuscular hemoglobin (MCH), indicating reduced hemoglobin content per cell. MCH may become abnormal before MCV. Red-cell distribution width (RDW), a measure of variation in cell size, typically increases as differently sized cells enter circulation. These findings support iron deficiency but are not specific: normal cell size does not exclude it, particularly when another deficiency or chronic disease alters the red-cell indices. Diagnosis therefore combines the blood count with biochemical evidence of iron depletion or restricted iron availability. (pmc.ncbi.nlm.nih.gov)

The World Health Organization’s 2024 guideline defines anemia by hemoglobin concentrations below 120 g/L in nonpregnant women and below 130 g/L in men aged 15–65 years. Pediatric thresholds are below 105 g/L at 6–23 months, 110 g/L at 24–59 months, 115 g/L at 5–11 years, and 120 g/L at 12–14 years for both sexes. During pregnancy, thresholds are below 110 g/L in the first and third trimesters and below 105 g/L in the second. These thresholds identify anemia, not its cause. WHO specifies adjustments for residential elevation and smoking, applied by subtracting the adjustment from measured hemoglobin or adding it to the diagnostic cutoff. For example, residence at 1,000–1,499 metres entails an 8 g/L adjustment; smoking 10–19 cigarettes daily entails a 5 g/L adjustment. Venous blood measured with an automated hematology analyzer is the preferred measurement approach. (ncbi.nlm.nih.gov)

Serum ferritin is the principal marker of stored iron. The 2021 British Society of Gastroenterology guideline identifies concentrations below 15 µg/L as indicating absent stores and below 30 µg/L as generally indicating low stores; a 45 µg/L cutoff offers a different sensitivity–specificity balance in clinical assessment. Ferritin is also an acute-phase protein, so inflammation can produce an apparently normal or elevated result despite deficiency. WHO’s 2020 ferritin guideline conditionally permits a threshold below 70 µg/L in adults with infection or inflammation. These cutoffs address different clinical circumstances and are not interchangeable; inflammatory markers and other iron studies provide context for interpretation. (pmc.ncbi.nlm.nih.gov)

Transferrin saturation expresses serum iron relative to total iron-binding capacity. Values below 20% indicate iron restriction but do not alone distinguish depleted stores from inflammatory sequestration. Absolute iron deficiency commonly produces low serum iron with increased iron-binding capacity, whereas anemia of inflammation generally has low serum iron, reduced iron-binding capacity, and preserved or elevated ferritin; both disorders may coexist. Reticulocyte hemoglobin measures the iron supply available to newly produced cells and can reveal restricted erythropoiesis. Soluble transferrin receptor is another supplementary marker, although increased erythropoietic activity, including that associated with thalassemia, can elevate it independently of depleted stores. (doi.org)

In thalassemia trait, microcytosis may be disproportionately pronounced relative to anemia, the red-cell count may remain normal or high, and RDW is often less increased than in iron deficiency. Persistent microcytosis with normal iron studies is evaluated through hemoglobin analysis, including hemoglobin A2 measurement for suspected beta-thalassemia. Sideroblastic anemia instead reflects defective iron utilization: iron stores and saturation are commonly increased, and marrow examination demonstrates iron-laden mitochondria arranged around erythroblast nuclei as ring sideroblasts. Concurrent vitamin B12 or folate deficiency can counterbalance iron-related microcytosis, leaving a normal average MCV despite abnormal cell populations; blood-film findings and separate nutrient measurements help identify these mixed deficiencies. (arupconsult.com)

Investigation of the Underlying Cause

The clinical history identifies possible sources of iron loss and impaired absorption: dietary restriction, menstrual bleeding, recent pregnancy, repeated blood donation, gastrointestinal surgery, and use of nonsteroidal anti-inflammatory drugs or aspirin. Gastrointestinal questions cover visible bleeding, altered bowel habits, abdominal pain, swallowing difficulty, and weight loss; family history may identify increased colorectal cancer risk. Previous complete blood counts and iron studies establish duration and whether earlier correction was sustained. Physical examination can reveal abdominal masses or signs of liver disease associated with gastrointestinal bleeding, but symptoms and examination findings alone cannot reliably localize an occult source. (bsg.org.uk)

Initial investigation also addresses nonintestinal blood loss and malabsorption. The 2021 British Society of Gastroenterology (BSG) guideline includes urinalysis or urine microscopy; persistent microscopic hematuria warrants urological investigation. It reports celiac disease in approximately 3%–5% of patients investigated for iron-deficiency anemia. Screening commonly uses tissue-transglutaminase antibodies, with duodenal biopsy providing histological confirmation. The 2020 American Gastroenterological Association (AGA) guideline favors initial serology, followed by biopsy if positive, in asymptomatic adults with plausible celiac disease. Negative serology does not invariably exclude disease when clinical evidence of malabsorption remains strong. (bsg.org.uk)

Unexplained anemia in adult men and women after menopause receives particular attention because chronic occult gastrointestinal bleeding is a frequent mechanism, and malignancy may present without localizing symptoms. The BSG guideline estimates that approximately one-third have an underlying pathological abnormality, most often gastrointestinal; this figure is not a cancer prevalence estimate. Both BSG and AGA guidelines support bidirectional endoscopy—upper gastrointestinal endoscopy and colonoscopy—in these groups. Upper examination can identify peptic ulcers and obtain duodenal biopsies; colonoscopy evaluates colorectal tumors and other bleeding lesions. For asymptomatic premenopausal women, AGA conditionally favors bidirectional endoscopy, whereas BSG generally reserves it for additional concerning features after celiac screening, such as disproportionate persistent or recurrent anemia or substantial hereditary risk. (bsg.org.uk)

CT colonography is a selected alternative when colonoscopy is unsuitable. It is less invasive and avoids sedation, but can miss subtle mucosal lesions and cannot obtain biopsies or remove polyps; an abnormal result may therefore require colonoscopy. When bidirectional endoscopy identifies no cause, the AGA guideline additionally suggests noninvasive testing for Helicobacter pylori. (bsg.org.uk)

Small-bowel assessment is selective rather than automatic after negative upper and lower examinations. In uncomplicated asymptomatic cases, AGA favors an initial trial of iron replacement before routine capsule endoscopy. Recurrent anemia or inadequate response despite acceptable-quality examinations can prompt small-bowel investigation and reassessment of the renal tract. Capsule endoscopy visualizes mucosal vascular lesions, ulcers, and inflammatory changes beyond conventional endoscopic reach. CT or MR enterography complements it when inflammatory or neoplastic disease is suspected. Device-assisted enteroscopy can subsequently obtain tissue or treat lesions identified by capsule examination. (gastro.org)

Iron Replacement and Other Clinical Treatments

Oral iron commonly uses ferrous sulfate, ferrous fumarate, or ferrous gluconate. These preparations supply different proportions of elemental iron, so the mass of the iron salt is not equivalent to the amount of iron delivered. Ferrous salts are generally more bioavailable than ferric salts because of their greater solubility. Absorption occurs predominantly in the duodenum and proximal small intestine; absorbed iron becomes available for hemoglobin synthesis and replenishment of body stores. Food can reduce absorption, although administration with food may improve gastrointestinal tolerance. Reduced gastric acidity, including that associated with proton-pump inhibitors, can impair absorption. (ods.od.nih.gov)

Nausea, abdominal discomfort, constipation, diarrhea, vomiting, and a metallic taste can limit oral treatment. Clinical adjustments include changing the preparation, reducing the amount administered, or altering the administration schedule; the balance is between iron delivery and tolerability rather than simply maximizing tablet strength. (nhlbi.nih.gov) The regulatory hormone hepcidin also affects uptake: an oral iron dose can temporarily raise hepcidin and reduce absorption from subsequent doses. A stable-isotope crossover study by Nicole U. Stoffel and colleagues, published online in 2019, examined 19 women with iron-deficiency anemia and found higher fractional absorption with alternate-day than consecutive-day administration. Hepcidin increased at 24 hours and returned toward baseline by 48 hours. These absorption findings explain the physiological rationale for less frequent schedules, but do not establish that every patient experiences faster hemoglobin recovery. (pubmed.ncbi.nlm.nih.gov)

Intravenous iron bypasses intestinal absorption and is used when oral treatment is ineffective, poorly tolerated, or unsuitable, or when iron must be delivered more rapidly. Examples include substantial continuing blood loss, malabsorption, and iron deficiency complicated by inflammation. Formulations include iron sucrose, ferric carboxymaltose, and ferric derisomaltose; their administration requirements differ, with some permitting replacement in fewer infusions. Intravenous delivery replenishes available iron but does not immediately supply functioning red cells. Infusion-related reactions can include flushing and chest or back discomfort; serious hypersensitivity reactions are uncommon, but administration requires facilities capable of recognizing and managing them. (pmc.ncbi.nlm.nih.gov)

Hypophosphatemia is a formulation-dependent adverse effect, particularly associated with ferric carboxymaltose. In two randomized trials reported by Myles Wolf and colleagues in JAMA in 2020, 245 adults who were intolerant of or unresponsive to oral iron received ferric derisomaltose or ferric carboxymaltose. Over 35 days, phosphate concentrations below 2.0 mg/dL occurred in 7.9% versus 75.0% of participants in one trial and 8.1% versus 73.7% in the other. Participants with reduced kidney function were excluded, and these figures describe biochemical hypophosphatemia, not rates of symptomatic bone disease. (pubmed.ncbi.nlm.nih.gov) Increased activity of fibroblast growth factor 23 promotes phosphate loss through the kidneys. Persistent hypophosphatemia can impair bone mineralization and has been associated with osteomalacia and fractures after repeated exposure. A November 2020 UK regulatory warning identified repeated high-dose treatment, prolonged treatment, and pre-existing risk factors as circumstances requiring phosphate monitoring. (gov.uk)

Red-cell transfusion differs from iron replacement because it supplies circulating erythrocytes and promptly increases oxygen-carrying capacity. In iron-deficiency anemia, it is generally reserved for severe symptomatic disease or circulatory compromise rather than used routinely to correct depleted stores; iron replacement may still be required afterward. (pmc.ncbi.nlm.nih.gov) Neither intervention removes the cause of negative iron balance. Treatment may therefore also involve control of menstrual or gastrointestinal bleeding, management of malabsorption, or modification of a causative medication. Iron therapy corrects the deficiency while these measures address the process producing it. (nhlbi.nih.gov)

Response, Recurrence, and Refractory Disease

Recovery of hemoglobin and replenishment of iron stores are separate outcomes: iron sufficient to support renewed red-cell production does not necessarily replace the reserves depleted before treatment. Hemoglobin recovery is followed through serial complete blood counts, while ferritin and other iron-status measurements address the remaining deficiency. The 2021 British Society of Gastroenterology guideline describes monitoring hemoglobin during the first four weeks and continuing iron replacement for approximately three months after hemoglobin normalization to replenish stores. Ferritin requires interpretation alongside inflammation, which can raise its concentration independently of iron reserves; the guideline notes insufficient evidence for routine ferritin monitoring in every treated adult. (doi.org)

Early hemoglobin change provides a measurable indication of treatment effectiveness. In a pooled analysis published in 2016, Maureen M. Okam and colleagues examined 738 participants receiving oral iron in five randomized trials. Of these, 537 achieved a hemoglobin increase of at least 10 g/L by day 14. By days 42–56, 92.9% of these early responders had achieved an increase of at least 20 g/L, compared with 27.4% of early nonresponders. The day-14 response predicted the later response with 90.1% sensitivity and 79.3% specificity. These results support early reassessment, but derive from a post hoc analysis of selected trial populations rather than establishing an invariant recovery timetable for every patient. (haematologica.org)

An inadequate response may reflect continuing blood loss, impaired intestinal absorption, gastrointestinal intolerance or nonadherence, concurrent systemic or bone-marrow disease, hemolysis, or an incomplete initial diagnosis, including additional vitamin B12 or folate deficiency. Persistent disease means iron-deficient hematological abnormalities remain despite adequate replacement; recurrent disease means they resolve and subsequently reappear. The 2021 guideline reports recurrence in approximately 12%–25% of adults who previously had negative upper and lower gastrointestinal endoscopy and a complete treatment response. This estimate concerns that investigated population, not all treated patients. Periodic blood counts can detect recurrence, which may prompt renewed assessment of the underlying cause. (doi.org)

Rare inherited iron-refractory iron-deficiency anemia (IRIDA) differs from these acquired causes of treatment failure. In 2008, Karin E. Finberg and colleagues identified germline mutations in TMPRSS6 in affected families. The gene encodes matriptase-2, a liver-expressed transmembrane serine protease involved in regulating hepcidin. In the classic, usually recessively inherited disorder, hepcidin is not appropriately suppressed by iron deficiency, limiting intestinal iron entry into the circulation and the availability of stored iron. Experimental work in Tmprss6-deficient mice demonstrated increased hepcidin, reduced intestinal ferroportin expression, and iron accumulation within intestinal absorptive cells. The characteristic human phenotype combines markedly microcytic, hypochromic anemia, low transferrin saturation, little or no oral-iron response, and a slow, incomplete response to intravenous iron. (pmc.ncbi.nlm.nih.gov)

The term iron-refractory nevertheless encompasses variable treatment responses. A Dutch study published in 2016 described 21 affected individuals diagnosed between 2010 and 2015. Among 14 with variants affecting both TMPRSS6 alleles, two responded slowly to oral iron and another responded to oral iron combined with vitamin C. The remaining 11 were unresponsive to oral iron and showed only partial improvement following parenteral iron or transfusion; transferrin saturation remained below 10% in nine of them. Molecular findings therefore require interpretation alongside the clinical phenotype and exclusion of acquired causes, rather than equating any failed oral-iron course with IRIDA. (pmc.ncbi.nlm.nih.gov)

Life-Stage and Chronic-Disease Contexts

Full-term infants generally begin life with iron reserves sufficient for approximately the first 4–6 months. Premature and low-birthweight infants have smaller reserves and can be vulnerable to deficiency from birth; rapid growth simultaneously increases the iron needed to expand circulating red-cell mass. Breast milk contains readily absorbed iron, but its iron content alone becomes insufficient to meet requirements after about 4–6 months. The transition to complementary foods therefore marks a change from dependence on neonatal stores to dependence on dietary iron. Iron-containing foods, such as meat and iron-fortified cereals, and iron-fortified formula provide distinct sources during this transition. The United States dietary reference intake for infants aged 7–12 months is 11 mg/day, a nutritional reference value rather than a treatment dose. Childhood growth continues to increase requirements, while adolescence can combine growth-related demand with menstrual iron loss. (ods.od.nih.gov)

During pregnancy, expansion of maternal red-cell mass and iron transfer to the fetus increase iron requirements; the United States recommended dietary allowance rises from 18 mg/day for nonpregnant women aged 19–50 to 27 mg/day during pregnancy. This increased requirement must be distinguished from physiological hemodilution. The American College of Obstetricians and Gynecologists’ 2021 practice bulletin describes plasma-volume expansion of approximately 40–50%, compared with a 15–25% increase in red-cell mass during singleton pregnancy. Because plasma expands proportionately more, measured hemoglobin concentration can fall despite an increase in the total circulating red-cell mass. Hemodilution does not itself establish iron depletion: iron-deficiency anemia requires evidence of deficient iron availability as well as anemia assessed against pregnancy-specific thresholds. Blood loss at delivery can further reduce iron stores, and postpartum anemia may reflect both pre-existing deficiency and acute hemorrhage. A 2016 World Health Organization guideline identifies antenatal anemia as a strong predictor of postpartum anemia and notes that depleted stores can persist for several months after childbirth. (ods.od.nih.gov)

In inflammatory bowel disease, iron depletion and inflammatory restriction frequently overlap. Ulcerated intestinal mucosa can produce continuing blood loss, while reduced intake and impaired absorption contribute additional deficits. At the same time, inflammatory signals increase hepatic hepcidin, reducing intestinal absorption and the release of recycled iron from macrophages. Iron can consequently remain in storage while its availability to the bone marrow declines. The European Crohn’s and Colitis Organisation’s 2015 consensus distinguished this mixed pattern from uncomplicated deficiency: serum ferritin below 30 µg/L supports iron deficiency without active inflammation, whereas values up to 100 µg/L can still be compatible with deficiency during inflammation. Ferritin between 30 and 100 µg/L in an inflammatory setting was identified as suggestive of combined iron deficiency and anemia of chronic disease. These context-dependent interpretations reflect ferritin’s behavior as an acute-phase protein, not different physiological requirements for iron. (academic.oup.com)

Chronic kidney disease introduces a separate limitation: damaged kidneys produce less erythropoietin, weakening the signal that stimulates red-cell production. Shortened red-cell survival, inflammation, nutritional deficiencies, and blood loss—particularly during dialysis—can coexist with this hormonal deficit. Consequently, renal anemia is not synonymous with iron-deficiency anemia, although depleted stores or restricted iron availability may contribute substantially. Uncomplicated renal anemia is usually normocytic and normochromic; the absence of small, pale red cells therefore does not resolve whether iron deficiency also exists. Assessment separates the adequacy of iron supply from the adequacy of erythropoietic stimulation. (niddk.nih.gov)

In heart failure, reduced dietary intake, impaired intestinal absorption, and gastrointestinal iron losses can coexist with inflammatory iron restriction. A 2025 Austrian Society of Cardiology position statement describes how inflammation and hepatic congestion can increase hepcidin expression, limiting absorption and mobilization of stored iron. Iron deficiency may occur with or without anemia: iron is required not only for hemoglobin synthesis but also for cellular energy metabolism in cardiac and skeletal muscle. Thus, studies of iron deficiency in heart failure cannot automatically be interpreted as studies of iron-deficiency anemia. Inflammatory elevation of ferritin further complicates assessment, making transferrin saturation relevant to the distinction between stored iron and iron available to tissues. (pmc.ncbi.nlm.nih.gov)

Prevention and Public-Health Programs

Food-based prevention combines adequate iron intake with attention to the proportion absorbed. Meat and seafood supply heme iron, whereas legumes, vegetables, and iron-fortified foods predominantly supply nonheme iron. The US National Institutes of Health estimates iron bioavailability at approximately 14–18% from mixed diets containing substantial meat, seafood, and vitamin C, compared with 5–12% from vegetarian diets; these are broad dietary estimates rather than fixed absorption rates for individuals. Vitamin C enhances nonheme iron absorption, while phytates in grains and legumes and some polyphenols reduce it. Dietary diversification therefore concerns both iron content and meal composition, including the availability of vitamin-C-rich foods alongside plant iron sources. Fortified breakfast cereals are another source, although their iron content varies between products. (ods.od.nih.gov)

Food fortification adds iron to commonly consumed foods without requiring each recipient to take a supplement. In its 2022 wheat-flour guideline, the World Health Organization (WHO) recommended fortification with highly bioavailable iron where industrially processed flour is regularly consumed by large population groups. Program design depends on consumption levels, flour extraction rate, existing nutrient deficiencies, other fortified foods, and supplement use. The iron compound must balance bioavailability, cost, and effects on taste, color, and storage acceptability. National standards, production quality control, and monitoring of actual household consumption are integral components: adding iron at a mill does not establish that the intended population receives an adequate amount. The guideline classified its iron recommendation as strong but based on low-certainty evidence, distinguishing a policy recommendation from certainty about the magnitude of benefit in every setting. (who.int)

Targeted supplementation programs address population groups whose requirements or dietary gaps may not be met through food-based measures alone. WHO’s 2016 guidance recommends daily iron supplementation for menstruating adult women and adolescent girls in settings where anemia prevalence in that group is at least 40%. Its corresponding infant-and-child guideline identifies children aged 6–23 months in settings with anemia prevalence of at least 40% as another target group. These thresholds concern all-cause anemia, not measured prevalence of iron-deficiency anemia, and define population interventions rather than individual treatment decisions. Iron-containing micronutrient powders added to complementary foods provide a separate point-of-use fortification approach. Selection among these strategies requires attention to local dietary patterns, age-specific burden, and other interventions already supplying iron. (who.int)

Infection control addresses mechanisms that iron provision alone does not remove. Hookworms cause chronic intestinal blood loss; in endemic areas, periodic deworming, sanitation improvements, and health education are complementary preventive measures. In malaria-endemic settings, WHO specifies that childhood iron supplementation should accompany measures to prevent, diagnose, and treat malaria. Insecticide-treated nets, appropriate malaria prevention programs, and access to treatment thus form part of the surrounding intervention system. These components are selected according to local transmission and disease burden rather than applied uniformly to every population with anemia. (who.int)

Evaluation distinguishes delivery indicators from biological outcomes. Fortification monitoring assesses nutrient levels and consumption, while population surveys measure both hemoglobin and iron-status indicators such as ferritin. WHO’s 2020 ferritin guideline recommends concurrent measurement of C-reactive protein and alpha-1-acid glycoprotein where infection or inflammation is widespread, because inflammation can elevate ferritin and obscure depleted stores. Prespecified adjustment methods are needed for comparable baseline and follow-up estimates. A fall in anemia prevalence alone does not establish a reduction attributable to iron: malaria control, changes in other nutrient deficiencies, and overlapping interventions can also affect hemoglobin. Evaluation therefore reports anemia, iron deficiency, and their coexistence separately, while documenting concurrent programs and changes in infection burden. (cdn.who.int)

References

1. Executive summary - Guideline on haemoglobin cutoffs to define anaemia in individuals and populationsncbi.nlm.nih.gov
2. Current understanding of iron homeostasispmc.ncbi.nlm.nih.gov
3. Iron Homeostasis in Health and Diseasepmc.ncbi.nlm.nih.gov
4. HEPCIDIN AND IRON HOMEOSTASISpmc.ncbi.nlm.nih.gov
5. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalizationpubmed.ncbi.nlm.nih.gov
6. Free erythrocyte protoporphyrin (FEP) II. The FEP test is clinically useful in classifying microcytic RBC disorders in adults.pubmed.ncbi.nlm.nih.gov
7. British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adultsbsg.org.uk
8. Anemia - Iron-Deficiency Anemia | NHLBI, NIHnhlbi.nih.gov
9. British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults - PMCpmc.ncbi.nlm.nih.gov
10. General donor assessment - Blood Donor Selectionncbi.nlm.nih.gov
11. A randomized, blinded, placebo-controlled trial of education and iron supplementation for mitigation of iron deficiency in regular blood donorspmc.ncbi.nlm.nih.gov
12. Celiac Disease - NIDDKniddk.nih.gov
13. Anaemiawho.int
14. Anaemia in women and childrenwho.int
15. Iron, Anemia, and Iron Deficiency Anemia among Young Children in the United Statespmc.ncbi.nlm.nih.gov
16. Iron status of toddlers, nonpregnant females, and pregnant females in the United Statespmc.ncbi.nlm.nih.gov
17. EVIDENCE AND RECOMMENDATIONS — WHO guideline on use of ferritin concentrations to assess iron status in individuals and populationsncbi.nlm.nih.gov
18. WHO guidance helps detect iron deficiency and protect brain developmentwho.int
19. Evaluation of Anemia - Hematology - Merck Manual Professional Editionmerckmanuals.com
20. Palpitations - Cardiology - MSD Manual Professional Editionmsdmanuals.com
21. Restless Legs Syndrome | National Institute of Neurological Disorders and Strokeninds.nih.gov
22. Overview of Heart Failure - Cardiology - Merck Manual Professional Editionmerckmanuals.com
23. Double burden of iron deficiency in infancy and low socioeconomic status: a longitudinal analysis of cognitive test scores to age 19 years.pubmed.ncbi.nlm.nih.gov
24. Summary of the evidence — Guideline on haemoglobin cutoffs to define anaemia in individuals and populationsncbi.nlm.nih.gov
25. EVIDENCE AND RECOMMENDATIONS — WHO guideline on use of ferritin concentrations to assess iron status in individuals and populationsncbi.nlm.nih.gov
26. Recommendations for diagnosis, treatment, and prevention of iron deficiency and iron deficiency anemiapmc.ncbi.nlm.nih.gov
27. Iron Deficiency Anemia and Anemia of Chronic Disease/Anemia of Inflammation Testingarupconsult.com
28. Microcytic Anemia Testingarupconsult.com
29. British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adultsbsg.org.uk
30. Gastrointestinal evaluation of iron deficiency anemiagastro.org
31. AGA Technical Review on Gastrointestinal Evaluation of Iron Deficiency Anemiapmc.ncbi.nlm.nih.gov
32. Anemia - Iron-Deficiency Anemianhlbi.nih.gov
33. Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic womenpubmed.ncbi.nlm.nih.gov
34. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trialspubmed.ncbi.nlm.nih.gov
35. Ferric carboxymaltose (Ferinject▼): risk of symptomatic hypophosphataemia leading to osteomalacia and fracturesgov.uk
36. Anemia - Treatment and Managementnhlbi.nih.gov
37. Iron deficiency anemia treatment response to oral iron therapy: a pooled analysis of five randomized controlled trialshaematologica.org
38. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA)pmc.ncbi.nlm.nih.gov
39. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA)nature.com
40. Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasispubmed.ncbi.nlm.nih.gov
41. Iron refractory iron deficiency anemia: a heterogeneous disease that is not always iron refractorypmc.ncbi.nlm.nih.gov
42. ACOG Practice Bulletin: Anemia in Pregnancyacinoedudoc.com
43. Iron Supplementation in Postpartum Womenncbi.nlm.nih.gov
44. Anemia in Chronic Kidney Disease - NIDDKniddk.nih.gov
45. Treat Complications & Comorbidities - NIDDKniddk.nih.gov
46. Diagnosis and treatment of iron deficiency in chronic heart failure: Position statement of the heart failure working group of the Austrian Society of Cardiologypmc.ncbi.nlm.nih.gov
47. Guideline: fortification of wheat flour with vitamins and minerals as a public health strategywho.int
48. Fortification of wheat flour with vitamins and minerals: executive summarycdn.who.int
49. Daily iron supplementation in adult women and adolescent girlswho.int
50. Daily iron supplementation in adult women and adolescent girls: guidelinewho.int
51. Daily iron supplementation in infants and children: guidelineiris.who.int
52. Food fortificationwho.int
53. Soil-transmitted helminth infectionswho.int
54. Daily iron supplementation in children and adolescents 5–12 years of age in malaria-endemic areaswho.int
55. Interventions to reduce anaemia by sectoranaemiaalliance.who.int